Business
Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025
BANGALORE, India, October 22, 2025--Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025.
About this update from Dr. Reddy's Laboratories Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/cb3cf2133dbbef1492f29c8fe60dfa63"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/JL2VQysZAf9hzel2n5Ofbg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/cb3cf2133dbbef1492f29c8fe60dfa63","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/q0Zf2OT3IJWZ5i8DAZWyuA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/cb3cf2133dbbef1492f29c8fe60dfa63","width":1024,"height":512}},"lazy":false},{"type":"text","content":"BANGALORE, India, October 22, 2025--(BUSINESS WIRE)--Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced that it will present new data from its proprietary Targeted Protein Degradation (TPD) and Proximity Inducer Platform (A-PROX) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held at the Hynes Convention Center in Boston, MA, from October 22–26, 2025.","length":479,"tagName":"p"},{"type":"text","content":"Aurigene’s A-PROX platform integrates library screening, direct-to-biology chemistries, proprietary ternary complex assays, modelling algorithms, and structure-based design to accelerate the discovery and optimization of both protein degraders, molecular glues and proximity inducers.","length":284,"tagName":"p"},{"type":"text","content":"Through this integrated approach, Aurigene has advanced a strong pre-clinical portfolio of next-generation degraders, including a SMARCA2-selective degrader, which recently received Investigational New Drug (IND) approval from the United States Food and Drug Administration (FDA); a pan-KRAS degrader; a SMARCA4-selective degrader; and a p300 degrader.","length":352,"tagName":"p"},{"type":"text","content":""Our A-PROX platform represents a significant step forward in the rational discovery of targeted protein degraders and molecular glues," said Dr. Murali Ramachandra, CEO of Aurigene Oncology Ltd. "We are excited to share our progress at the AACR-NCI-EORTC conference and continue advancing differentiated therapies that have the...